Does Dr. MOHAMED AYMAN have financial conflicts of interest?

Dr. MOHAMED AYMAN (MD) has received a total of $2,080 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $2,080 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MOHAMED AYMAN?

According to CMS Open Payments data, Dr. MOHAMED AYMAN received funding from MEDICAL DEVICE BUSINESS SERVICES ($427), UNITED THERAPEUTICS CORPORATION ($270), and GENZYME CORPORATION ($251).

Does Dr. MOHAMED AYMAN receive research grants or speaking fees?

Dr. MOHAMED AYMAN has received $2,080 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MOHAMED AYMAN

MDReal-Time Hydrated

Specialty: Internal Medicine, Pulmonary Disease

Practice Location: SAGINAW, MI 48601

NPI Number: 1679131957

LIFETIME INDUSTRY VALUE

$2,080

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. AYMAN is a verified Internal Medicine, Pulmonary Disease practitioner based in SAGINAW, MI.

Between 2021 and 2024, Dr. AYMAN had an overall industry promotional and research financial footprint of $2,080 as recorded in the federal CMS Open Payments database.

$2,080 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. AYMAN's primary funding source is MEDICAL DEVICE BUSINESS SERVICES, which accounts for $427 (representing 20.5% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

MEDICAL DEVICE BUSINESS SERVICES

Rank 1

$427

20.5%

UNITED THERAPEUTICS CORPORATION

Rank 2

$270

13%

GENZYME CORPORATION

Rank 3

$251

12.1%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.